DexCom (DXCM) reported Q1 non-GAAP earnings late Thursday of $0.32 per diluted share, unchanged from a year earlier.
Analysts surveyed by FactSet expected $0.33.
Revenue for the quarter ended March 31 rose to $1.04 billion from $921.0 million a year earlier.
Analysts surveyed by FactSet expected $1.02 billion.
The company maintained its full-year 2025 revenue guidance of $4.60 billion. Analysts expected $4.61 billion.
DexCom said its board has approved a share repurchase program of up to $750 million, with a repurchase period ending no later than June 30, 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.